BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 22113614)

  • 1. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
    Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
    Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.
    Sun D; Stopka-Farooqui U; Barry S; Aksoy E; Parsonage G; Vossenkämper A; Capasso M; Wan X; Norris S; Marshall JL; Clear A; Gribben J; MacDonald TT; Buckley CD; Korbonits M; Haworth O
    Cell Rep; 2019 Apr; 27(5):1461-1471.e4. PubMed ID: 31042473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.
    Pighi C; Cheong TC; Compagno M; Patrucco E; Arigoni M; Olivero M; Wang Q; López C; Bernhart SH; Grande BM; Poggio T; Langellotto F; Bonello L; Dall'Olio R; Martínez-Martín S; Molinaro L; Francia di Celle P; Whitfield JR; Soucek L; Voena C; Calogero RA; Morin RD; Staudt LM; Siebert R; Zamò A; Chiarle R
    Blood Adv; 2021 Dec; 5(23):5239-5257. PubMed ID: 34625792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease.
    Schneider C; Kon N; Amadori L; Shen Q; Schwartz FH; Tischler B; Bossennec M; Dominguez-Sola D; Bhagat G; Gu W; Basso K; Dalla-Favera R
    Blood; 2016 Aug; 128(5):660-6. PubMed ID: 27166359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma.
    van Engelen N; van Dijk F; Waanders E; Buijs A; Vermeulen MA; Loeffen JLC; Kuiper RP; Jongmans MCJ
    Fam Cancer; 2021 Oct; 20(4):349-354. PubMed ID: 33811277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis.
    Yang CH; Pfeffer SR; Sims M; Yue J; Wang Y; Linga VG; Paulus E; Davidoff AM; Pfeffer LM
    J Biol Chem; 2015 Mar; 290(10):6037-46. PubMed ID: 25589783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cullin-associated and neddylation-dissociated 1 regulate reprogramming of lipid metabolism through SKP1-Cullin-1-F-box
    Zhang H; Xia P; Yang Z; Liu J; Zhu Y; Huang Z; Zhang Z; Yuan Y
    Clin Transl Med; 2023 Oct; 13(10):e1443. PubMed ID: 37837399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration.
    Abbas T; Mueller AC; Shibata E; Keaton M; Rossi M; Dutta A
    Mol Cell; 2013 Mar; 49(6):1147-58. PubMed ID: 23478445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
    Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
    Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis.
    Zheng H; Shen M; Zha YL; Li W; Wei Y; Blanco MA; Ren G; Zhou T; Storz P; Wang HY; Kang Y
    Cancer Cell; 2014 Sep; 26(3):358-373. PubMed ID: 25203322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic psychological stress impairs germinal center response by repressing miR-155.
    Sun W; Zhang L; Lin L; Wang W; Ge Y; Liu Y; Yang B; Hou J; Cheng X; Chen X; Wang Z
    Brain Behav Immun; 2019 Feb; 76():48-60. PubMed ID: 30414952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
    Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
    Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the CRL4(Cdt2) ubiquitin ligase and cell-cycle exit by the SCF(Fbxo11) ubiquitin ligase.
    Rossi M; Duan S; Jeong YT; Horn M; Saraf A; Florens L; Washburn MP; Antebi A; Pagano M
    Mol Cell; 2013 Mar; 49(6):1159-66. PubMed ID: 23478441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
    Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
    J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
    Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
    Polo JM; Juszczynski P; Monti S; Cerchietti L; Ye K; Greally JM; Shipp M; Melnick A
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3207-12. PubMed ID: 17360630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation.
    Jiang C; Trudeau SJ; Cheong TC; Guo R; Teng M; Wang LW; Wang Z; Pighi C; Gautier-Courteille C; Ma Y; Jiang S; Wang C; Zhao B; Paillard L; Doench JG; Chiarle R; Gewurz BE
    Cell Rep; 2019 Jul; 28(5):1307-1322.e8. PubMed ID: 31365872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
    Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
    J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
    Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
    Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.